Inventiva (IVA): The MASH Turnaround Play – 200% potential.
Summary: Inventiva SA is showing a compelling turnaround setup on the daily timeframe. After a prolonged accumulation period in the $3.50–$4.50 range, the price has successfully reclaimed key moving averages and broken out of a massive volume shelf. Backed by strong analyst upgrades (UBS, Leerink) and a fully funded Phase 3 MASH trial, the risk/reward ratio favors the bulls.
Technical Analysis (Chart breakdown):
Volume Profile Breakout: The visible Fixed Range Volume Profile (FRVP) on the right shows a massive "Value Area" between $3.00 and $4.50. The price ($5.71) has decisively cleared the Value Area High (VAH). This indicates that the heavy supply/overhead inventory has been absorbed. We are now in a "low volume node," where price can move rapidly due to lack of resistance.
Fibonacci Extension:
We have cleared the 23.6% Fib ($4.62) and the 38.2% Fib ($5.28), turning these former resistance levels into support.
Immediate Target: The 61.8% Golden Pocket at $6.34.
Secondary Target: The previous swing high (100% Fib) at $8.07.
Extension Targets: If the momentum continues, the 1.618 extension sits at $10.86, aligning closely with recent analyst price targets.
RSI: The RSI is trending upward and holding above the median 50 level, confirming strong bullish momentum without being significantly overbought yet.
Fundamental Analysis (The "Why" Now):
Clinical Catalyst (NATiV3): Inventiva’s lead drug, lanifibranor, is the only oral pan-PPAR agonist in Phase 3 for MASH (NASH). Recent updates confirm the trial is on track, with topline results expected in H2 2026.
Cash Runway Extended: The company recently secured ~$170M+ in financing (including a rights issue), removing the immediate dilution fear that suppressed the stock in 2024. This cash fully funds them through the Phase 3 data readout.
Analyst Sentiment: Recent initiations from major firms (e.g., UBS, Leerink) have slapped "Buy" ratings on IVA with targets ranging from $12 to $16, implying >150% upside from current levels.
MASH Sector Heat: With big pharma actively looking for MASH assets (following Madrigal's approval), Inventiva remains a prime acquisition target or partnership candidate.
Trade Plan:
Entry: Current levels or on a pullback retest of the $5.28 (38.2% Fib) support.
Stop Loss: A close back inside the volume shelf, below $4.40.
Target 1: $6.34 (61.8% Fib gap fill).
Target 2: $8.07 (Previous High).
Target 3 (Swing): $10.86 - $15.38 (Fib Extensions & Analyst PTs).
Technical Analysis (Chart breakdown):
Volume Profile Breakout: The visible Fixed Range Volume Profile (FRVP) on the right shows a massive "Value Area" between $3.00 and $4.50. The price ($5.71) has decisively cleared the Value Area High (VAH). This indicates that the heavy supply/overhead inventory has been absorbed. We are now in a "low volume node," where price can move rapidly due to lack of resistance.
Fibonacci Extension:
We have cleared the 23.6% Fib ($4.62) and the 38.2% Fib ($5.28), turning these former resistance levels into support.
Immediate Target: The 61.8% Golden Pocket at $6.34.
Secondary Target: The previous swing high (100% Fib) at $8.07.
Extension Targets: If the momentum continues, the 1.618 extension sits at $10.86, aligning closely with recent analyst price targets.
RSI: The RSI is trending upward and holding above the median 50 level, confirming strong bullish momentum without being significantly overbought yet.
Fundamental Analysis (The "Why" Now):
Clinical Catalyst (NATiV3): Inventiva’s lead drug, lanifibranor, is the only oral pan-PPAR agonist in Phase 3 for MASH (NASH). Recent updates confirm the trial is on track, with topline results expected in H2 2026.
Cash Runway Extended: The company recently secured ~$170M+ in financing (including a rights issue), removing the immediate dilution fear that suppressed the stock in 2024. This cash fully funds them through the Phase 3 data readout.
Analyst Sentiment: Recent initiations from major firms (e.g., UBS, Leerink) have slapped "Buy" ratings on IVA with targets ranging from $12 to $16, implying >150% upside from current levels.
MASH Sector Heat: With big pharma actively looking for MASH assets (following Madrigal's approval), Inventiva remains a prime acquisition target or partnership candidate.
Trade Plan:
Entry: Current levels or on a pullback retest of the $5.28 (38.2% Fib) support.
Stop Loss: A close back inside the volume shelf, below $4.40.
Target 1: $6.34 (61.8% Fib gap fill).
Target 2: $8.07 (Previous High).
Target 3 (Swing): $10.86 - $15.38 (Fib Extensions & Analyst PTs).
💻 Engineer | 📈 Investor | 🚀 Entrepreneur. Cofounder of Purdy Financials. Scanners, indicators, precise set-ups.
Join our community - discord.gg/nz3NYnfQDA
Join our community - discord.gg/nz3NYnfQDA
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。
💻 Engineer | 📈 Investor | 🚀 Entrepreneur. Cofounder of Purdy Financials. Scanners, indicators, precise set-ups.
Join our community - discord.gg/nz3NYnfQDA
Join our community - discord.gg/nz3NYnfQDA
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。